2 Union Square, Union City, CA 94587
contact@NeoBiotechnologies.com
510-376-5603

Home >> Antibodies >> Small Cell Lung Carcinoma Antigen (SCLC Marker)

Small Cell Lung Carcinoma Antigen (SCLC Marker)

Mouse Monoclonal Antibody [Clone MOC-52]

Catalog #

Size

20 ug
100 ug
100 ug

Price (USD)

219.00
499.00
499.00

Formulation

Purified Ab with BSA and Azide at 200ug/ml
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml

Catalog No

Size

20 ug
100 ug
100 ug

Formulation

Purified Ab with BSA and Azide at 200ug/ml
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml

Price (USD)

219.00
499.00
499.00
img

SDS-PAGE Analysis Purified SCLC Mouse Monoclonal Antibody (MOC-52). Confirmation of Purity and Integrity of Antibody.

Product Details

Synonyms

Not Known

Positive Control

Human small cell lung carcinoma, adrenal gland.

Known Applications & Suggested Dilutions

IF, ICC         More Details

Immunofluorescence (1-2ug/ml)
Immunocytochemistry (Frozen) (1-2ug/ml for 30 minutes at RT)
Optimal dilution for a specific application should be determined.

Immunogen

Lung Cancer-associated antigen isolated from small cell lung carcinoma-derived cell line

Cellular Localization

Cell Surface

Species Reactivity

Human.

Host / Ig Isotype

Mouse / IgG1, kappa

Mol. Weight of Antigen

145kDa

Specificity & Comments

This MAb reacts with a membrane-associated protein present in normal and malignant neuroendocrine tissues including small cell lung cancer (SCLC). It stains neural and a variable number of endocrine tissues and in the lung it reacts preferentially with SCLC and carcinoids. Its epitope is destroyed during formalin fixation. This antibody was categorized during the First International Workshop on Small Cell Lung Cancer Antigens held in London in April 1987. There are two major types of Lung Carcinoma: non-small cell, which accounts for 80% of all cases; and small cell, which accounts for roughly 20% of all lung cancers reported. The lung continues to be a customary place for cancer migration from tumors elsewhere in the body. Treatment depends on the specific cell type of the cancer, level of progression and status of the individual patient.

Related Products



200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Key References

  1. W.H.O., 1982, 2nd ed. Am J. Clin. Path. 77, 123-136.
  2. De Leij, L., et al., 1984, Eur. J. Canc. Clin. Oncol. 20, 123-128.
  3. Souhami, R.L., et al., 1987, Lancet ii, 325-326.
  4. De Leij, L., et al., 1987, In: Application of Monoclonal antibodies in tumor pathology (Ruiter DJ et al., eds), Dordrecht: Martinus Nijhoff, pp 191-210.
  5. Berendsen, H.H., de Leij, L., Postmus, P.E., Ter Haar, J.G., Poppema, S. and The, T.H. 1988. Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibody directed against neuroendocrine differentiation antigen. J. Clin. Pathol. 41: 273-276.

Bioinformatics

NBT00329